Active	Status	Sponsor type	Region	Phase	Filter
17 Active 0 Inactive 17 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Hanna, Diana
HOPE Kids 2, NCT04218084 / 2017-000903-26: Study to Evaluate the Effect of GBT440 on TCD in Pediatrics With Sickle Cell Disease	Terminated	3	236	Europe, US, RoW	Voxelotor, Placebo	Pfizer	Sickle Cell Disease	08/23	11/24
NCT05630183: A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer Jan 2024 - Jun 2024 : Results from C-800-22 trial for 2L metastatic pancreatic cancer	Recruiting	2	78	US	Botensilimab, AGEN1181, Gemcitabine, Nab-paclitaxel	Agenus Inc.	Metastatic Pancreatic Ductal Adenocarcinoma	12/24	12/24
KEYNOTE F92, NCT05597839: Study of DF9001 in Patients With Advanced Solid Tumors	Recruiting	1/2	242	US	DF9001, pembrolizumab, KEYTRUDA®	Dragonfly Therapeutics, Merck Sharp & Dohme LLC	Solid Tumor, Adult	08/25	11/27
TWINPEAK, NCT05482893: Spevatamig (PT886) for Treatment of Patients with Metastatic/Advanced Gastric, Gastroesophageal Junction and Pancreatic Adenocarcinoma (the Study)	Recruiting	1/2	135	US	Spevatamig (PT886), Paclitaxel, Gemcitabine, Abraxane, KEYTRUDA® (pembrolizumab), Oxaliplatin, Leucovorin, Fluorouracil, Capecitabine, FOLFIRINOX	Phanes Therapeutics, Merck Sharp & Dohme LLC	Gastric or Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma	12/27	04/28
XTX202-01, NCT05052268 / 2022-003078-21: XTX202 in Patients With Advanced Solid Tumors	Active, not recruiting	1/2	189	US	XTX202	Xilio Development, Inc., Xilio Development, Inc	Advanced Solid Tumor	02/26	02/26
NCT04250597: Study of GNX102 in Patients With Advanced Solid Tumors	Terminated	1	46	US, RoW	GNX102	GlycoNex, Inc.	Solid Tumor, Metastatic Cancer, Advanced Cancer, Unresectable Solid Neoplasm	07/23	07/23
NCT03854110: Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine	Recruiting	1	64	US	GP-2250, gemcitabine	Geistlich Pharma AG, Translational Drug Development	Pancreatic Cancer, Adult	09/24	12/24
TEAD-AST-101, NCT06251310: SW-682 in Advanced Solid Tumors	Recruiting	1	186	US	SW-682, Combination Therapy	SpringWorks Therapeutics, Inc.	Advanced Solid Tumor, Mesothelioma, Malignant	01/30	06/30
ZWI-ZW171-10, NCT06523803: A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers	Recruiting	1	160	Europe, US	ZW171	Zymeworks BC Inc.	Mesothelin-expressing Advanced Cancers	11/27	12/27